| HOME >> MEDICINE >> TECHNOLOGY |
Figure 55: China - indexed sales of Plavix and generic clopidogrel in the hospital segment, 2005-09 146
Figure 56: China - central government's policies in favor of biotech development, 2006-09 149
Figure 57: China - drivers and resistors of biosimilar uptake 150
Figure 58: China - launched and developmental biosimilars in China, 2010 153
Figure 59: China - drivers and resistors to biosimilar monoclonal antibody entry, 2010 157
Figure 60: China - drivers and resistors for foreign and domestic players in innovative drug R&D 159
Figure 61: China - advantages and disadvantages of conducting clinical trials in China 162
Figure 62: China - international and domestic M&A deals in the pharmaceutical sector carried out in China, 2008-2010 165
Figure 63: China - Pfizer's R&D and manufacturing presence compared with top 8 multinational companies in China, 2010 170
Figure 64: China - Pfizer's pharmaceutical operations (post-merger with Wyeth), 2010 171
Figure 65: China - AstraZeneca's R&D and manufacturing presence compared with top 8 multinational companies in China, 2010 177
Figure 66: China - AstraZeneca's pharmaceutical operations, 2010 178
Figure 67: China - Sanofi-Aventis R&D presence compared with top 8 multinational companies in China, 2010 182
Figure 68: China - Sanofi-Aventis's pharmaceutical operations, 2010 183
Figure 69: China - Bayer Schering R&D and manufacturing presence compared with top 8 multinational companies in China, 2010 186
Figure 70: China - Bayer Schering's pharmaceutical operations, 2010 187
Figure 71: China - Roche R&D and manufacturing presence compared with top 8 multinational companies in China, 2010 191
Figure 72: China - Roche's pharmaceutical operations, 2010 192
Figure 73: China - Shandong Qilu Pharma's pharmaceutical operations, 2010 196
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |